All In MedTech

Device Trial Radar · NCT02820077

Hemostatic Powder Versus Clinical Management for the Treatment of Upper Gastrointestinal Bleeding From Tumor Lesions

Randomized Controlled Trial of Hemostatic Powder Versus Optimal Clinical Management for the Treatment of Upper Gastrointestinal Bleeding From Tumor Lesions

Last checked: Nov 19, 2026Latest source record: Aug 31, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

62

Actual

Start

Aug 6, 2016

Primary completion

Jan 24, 2020

Study completion Aug 27, 2020

Sponsor

Lead sponsor
Instituto do Cancer do Estado de São PauloAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 30, 2016

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the efficacy of the endoscopic hemostatic powder for the treatment of bleeding from malignant lesions of the upper GI tract. Half of participants will receive hemostatic powder and half will be submitted to standard treatment.

Conditions

  • Gastrointestinal Hemorrhage
  • Gastrointestinal Neoplasms

Interventions

  • Hemospray (Endoscopic treatment with hemostatic powder)Device

    Malignant bleeding lesions will be treated with endoscopic powder and patients will receive optical clinical management afterwards

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. rebleedingTime frame: until 30 days after endoscopy
  2. mortalityTime frame: until 30 days after endoscopy

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.